Smith & Nephew SNATS Receivables 2010-2024 | SNN

Smith & Nephew SNATS receivables for the quarter ending June 30, 2024 were $1.333B, a 3.33% increase year-over-year.

  • Smith & Nephew SNATS receivables for 2023 were $1.333B, a 2.46% increase from 2022.
  • Smith & Nephew SNATS receivables for 2022 were $1.301B, a 0.85% increase from 2021.
  • Smith & Nephew SNATS receivables for 2021 were $1.29B, a 6.52% increase from 2020.

Smith & Nephew SNATS Receivables 2010-2024 | SNN

  • Smith & Nephew SNATS receivables for 2023 were $1.333B, a 2.46% increase from 2022.
  • Smith & Nephew SNATS receivables for 2022 were $1.301B, a 0.85% increase from 2021.
  • Smith & Nephew SNATS receivables for 2021 were $1.29B, a 6.52% increase from 2020.
Related Stocks
Company NameMarket
Cap
Abbott Laboratories (ABT)$204.2B
Stryker (SYK)$146.7B
Boston Scientific (BSX)$132.6B
EssilorLuxottica (ESLOY)$112.1B
Medtronic (MDT)$110.6B
Haleon (HLN)$43.7B
Lonza Group Ag (LZAGY)$42.2B
GE HealthCare Technologies (GEHC)$37.7B
ResMed (RMD)$35.8B
Terumo (TRUMY)$29.7B
Koninklijke Philips (PHG)$24.8B
Zimmer Biomet Holdings (ZBH)$21.9B
Insulet (PODD)$18.4B
Baxter (BAX)$17B
BellRing Brands (BRBR)$10.2B
Bio-Rad Laboratories (BIO)$9.3B
Demant (WILYY)$8.3B
Lantheus Holdings (LNTH)$6.3B
TG Therapeutics (TGTX)$5.5B
Haemonetics (HAE)$4.3B
Prestige Consumer Healthcare (PBH)$4.2B
ICU Medical (ICUI)$4.1B
Perrigo (PRGO)$3.8B
Envista Holdings (NVST)$3.7B
Neogen (NEOG)$3.2B
Agios Pharmaceuticals (AGIO)$3.2B
Shandong Weigao Medical Polymer (SHWGF)$3B
GN Store Nord (GNNDY)$2.8B
QuidelOrtho (QDEL)$2.7B
LeMaitre Vascular (LMAT)$2.4B